Free Consultation 215.567.2010

Robert S. Silver

Partner, Philadelphia

One of the most active intellectual property litigators in the country and Chairperson of the firm’s Litigation Department and ANDA Litigation Team, Robert Silver represents global and U.S. companies in a wide range of litigation. His litigation practice as lead counsel for large, world-wide generic companies has emphasized complex suits involving Abbreviated New Drug Applications (ANDA) containing Paragraph IV challenges under the Hatch-Waxman Act. Mr. Silver counsels clients on ANDA preparation and strategies and has prepared, tried, argued and settled ANDA litigation cases all over the country. Mr. Silver was also responsible for assisting a generic client launch the most successful and profitable at-risk launch in history with close to $1 billion in sales made in 5 days.

Awards & Recognition

  • Who’s Who Legal: Patents 2018-2019
  • Best Lawyers in America, 2018-2021
  • Pennsylvania Super Lawyer, 2004-2020
  • Martindale Hubbell AV Preeminent Rated
  • Chambers USA Top Ranked in Intellectual Property, 2010-2016
  • Senior Fellow Litigation Counsel of America, The Trial Lawyer Honorary Society
  • IAM Patent 1000 Ranked Attorney, 2014-2020
  • Top Attorneys in Pennsylvania Philadelphia Magazine 2018-2019
  • Best Lawyers in Pennsylvania 2019 Wall Street Journal
  • 2019 Global Law Experts IP Litigation Law Expert
  • The Actors Fund 2018 Encore Award for Performing Arts commitment
  • Trial Law Institute and Diversity Law Institute Member
  • IP Litigation Law Firm of the Year in Pennsylvania – 2020 Corporate International Magazine Global Award
  • The American Lawyer-Lawyer of Distinction 2020
  • National Law Journal Lawyers of Distinction 2020

Industries Served

  • Biomedical
  • Biotechnology
  • Chemical
  • Mechanical
  • Pharmaceuticals

Related Representative Matters

  • Boehringer et al. v. InvaGen (10/25/18 D.NJ) represented generic in ANDA litigation successfully invalidating asserted patents covering Tradjenta® (linagliptin) and Jentadueto® (linagliption and metformin)
  • Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership v. Apotex, Inc., represented generic in ANDA litigation on Plavix® involving largest at risk launch in history
  • Roxane Labs Inc. v. Invagen Inc., successfully represented defendant generic company in transferring case from Ohio to NJ, defeated Preliminary Injunction, affirmed on appeal and obtained stipulation of non-infringement, affirmed on appeal, in suit by another generic regarding calcium acetate tablets (PhosLo® brand) and ultimately awarded client $2 million in attorney fees finding the case “exceptional”
  • Genzyme v. Pentech Pharmaceuticals, Inc. represented generic in ANDA litigation on Hectorol® invalidating 2 Orange Book listed patents, with third patent being delisted as a result of suit
  • Biovail Laboratories, Inc. v. Torpharm. Inc., successfully represented generic company in ANDA litigation involving Tiazac® (diltiazem hydrochloride)

Related Posts


1635 Market Street, 12th Floor
Philadelphia, Pennsylvania 19103-2212

215-567-2010 | 215-751-1142

View Map

Lehigh Valley

1275 Glenlivet Drive, Suite 100
Allentown, Pennsylvania 18106

610-255-7551 | 610-255-7542

View Map